Genetic screening has confirmed that PARG deficiency induced PARPi resistance in mouse breast tumor cells, and even this mechanism was relatively common in BRCA2-deficient mouse breast tumor cell resistance [46]. This evidence concerns the gene BRCA2 and breast neoplasm.